Welcome to our dedicated page for QMMM Holdings Limited. SEC filings (Ticker: QMMM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering where QMMM’s project pipeline, client concentration, or virtual technology spend actually show up in the numbers? Every QMMM quarterly earnings report 10-Q filing and QMMM annual report 10-K simplified lives here, paired with Stock Titan’s AI summaries so you can grasp revenue recognition details without sifting through accounting jargon.
Start with what you need: How to read QMMM’s 10-K annual report? or Which directors filed a QMMM insider trading Form 4 transactions alert yesterday? Our platform answers those questions automatically. The moment an 8-K announces a new luxury-brand campaign, you’ll see “QMMM 8-K material events explained” right beside the original PDF. Curious about founder share sales? Real-time dashboards track every QMMM Form 4 insider transactions real-time update, including option exercises and executive stock transactions Form 4 disclosures.
Key tools you’ll use:
- AI-powered summaries that translate technical language into plain English—perfect for understanding QMMM SEC documents with AI in minutes.
- Instant EDGAR feeds so proxy statement executive compensation changes appear the second they’re filed.
- Side-by-side comparisons that link creative-tech R&D spend in successive 10-Qs for fast QMMM earnings report filing analysis.
Whether you’re monitoring a fresh ManyMany Creations contract disclosed in an 8-K or benchmarking Quantum Matrix revenue trends, this page keeps every filing type—10-K, 10-Q, 8-K, S-1, and more—organized and explained simply. Make informed decisions without wading through hundreds of pages; the insights that matter are already highlighted.
IMAC Holdings, Inc. (NASDAQ: BACK) filed a restated Form 10-Q/A for the quarter ended 30 June 2024. The amendment corrects previously issued statements after the Audit Committee determined preferred-dividend accounting was materially misstated. The restatement reallocates US$525k of accrued dividends from current liabilities to additional paid-in capital, but does not change total assets or net loss.
Operating results (continuing operations):
- Revenues: US$15.8k (precision-medicine collaboration fees).
- Gross loss: US$(56.3)k as initial lab start-up expenses exceeded sales.
- Operating loss: US$(1.40)m for the quarter; US$(1.81)m YTD.
- Net loss available to common holders: US$(2.03)m for the quarter; US$(2.52)m YTD, or US$(2.16) per share.
Balance sheet (30 Jun 24, restated):
- Cash rose to US$0.89 m from US$0.22 m at 31 Dec 23, helped by US$1.35 m of preferred-stock proceeds and a US$1.0 m net promissory-note raise.
- Total assets: US$2.22 m, including US$1.01 m of newly acquired lab equipment from Theralink.
- Current liabilities: US$3.99 m, driving a working-capital deficit of roughly US$(3.3) m.
- Stockholders’ deficit widened to US$(1.77) m.
Capital & financing actions: 43.5 k shares of Series C-2/D/E/F preferred stock and 2.8 m warrants issued, raising US$1.35 m; US$1.4 m face value 40 % OID notes issued for US$1.0 m cash. Subsequent to the quarter, the company:
- Raised an additional US$0.6 m (US$0.84 m face) via notes.
- Closed a US$3.74 m PIPE for Series G preferred shares and warrants, using US$2.24 m to retire earlier notes.
Strategic shift: All legacy clinics have been sold or closed; ongoing business is now Ignite Proteomics, a precision-medicine lab leveraging Theralink assets for breast-cancer protein analysis and pharma collaborations.
Risk & controls: Management expresses substantial doubt about going-concern status. Two material weaknesses (inadequate accounting resources and segregation-of-duties) remain unresolved. Multiple CMS audits on discontinued operations could trigger material repayments. A Tampa clinic lease is in default.
Outlook: Management must scale Ignite revenues, secure Medicare reimbursement, remediate control gaps and refinance expensive debt to alleviate liquidity pressure and justify the US$51 m preferred-stock liquidation preference outstanding.
The Securities and Exchange Commission has declared QMMM Holdings' Form F-1 registration statement effective as of June 20, 2025, at 9:00 A.M. The Form F-1 (File Number: 333-287066) marks a significant milestone for the foreign company as it indicates their intent to conduct an initial public offering (IPO) in the United States markets.
A Form F-1 is the standard registration form for foreign companies looking to list securities on U.S. exchanges. The effectiveness declaration means that QMMM Holdings can now proceed with its planned public offering and begin trading its securities, subject to other regulatory requirements and market conditions.
QMMM Holdings Limited, a Cayman Islands holding company with operations conducted through subsidiaries in Hong Kong, has filed a Rule 424(b)(4) prospectus for a best-efforts offering of up to 40,000,000 Class A ordinary shares at a fixed price of US$0.20 per share. The maximum gross proceeds are US$8.0 million; net proceeds before offering expenses are approximately US$7.52 million after placement-agent commissions of 6 % plus a 1 % expense allowance and up to US$100,000 in reimbursable costs. Shares trade on Nasdaq Capital Market under the symbol “QMMM” and last closed at US$0.96 on 18 June 2025, implying a deep discount of roughly 79 % to the market price. There is no minimum subscription and no escrow; funds will be available to the company immediately upon each sale. Pacific Century Securities, LLC and Revere Securities LLC act as exclusive placement agents without any obligation to purchase unsold shares. QMMM qualifies as an emerging growth company and will benefit from reduced reporting requirements.
The prospectus highlights significant regulatory and structural risks: QMMM is not an operating company; investors purchase Cayman-incorporated holding-company shares while all operations occur in Hong Kong. Although the group currently operates outside mainland China, PRC authorities could extend oversight to Hong Kong entities, potentially forcing restructuring, limiting capital transfers or rendering the shares worthless. The filing also discusses potential ramifications of the Holding Foreign Companies Accountable Act; QMMM’s U.S.-based auditor is presently inspectable by the PCAOB, but future rule changes could still lead to delisting. To date there have been no dividends or material cash transfers between the holding company and subsidiaries, and management has not committed to future distributions. Investors should review the detailed risk factors beginning on page 13 before purchasing shares.
FAQ
What is the current stock price of QMMM Holdings Limited. (QMMM)?
What is the market cap of QMMM Holdings Limited. (QMMM)?
What core services does QMMM Holdings Limited provide?
Which industries does QMMM Holdings cater to?
How does QMMM integrate technology into its creative process?
What role do the subsidiaries play in QMMM Holdings’ operations?
How does QMMM Holdings differentiate itself in the competitive digital advertising market?
What is the significance of QMMM’s approach to virtual technologies?
